{'fraction_non_alphanumeric': 0.017937219730941704, 'fraction_numerical': 0.004484304932735426, 'mean_word_length': 5.468599033816425, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Differential expression of Fanconi anemia complementation group I in triple negative breast cancer.

Women diagnosed with triple negative breast cancer are predicted to benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding Fanconi anemia complementation group I, FANCI, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). FANCI was also differentially expressed in bulk tumor in human breast cancer (3). FANCI mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of FANCI in primary tumors of the breast was correlated with overall survival in patients with basal-like and luminal A type cancer, while within triple negative breast cancer, primary tumor expression of FANCI was correlated with overall survival in patients with immunomodulatory subtype disease. FANCI may be of relevance to initiation, maintenance or progression of triple negative breast cancers.